Italia markets closed

Quantum Genomics Société Anonyme (0D1J.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,1602+0,0080 (+5,26%)
Alla chiusura: 05:41PM BST
Schermo intero
Chiusura precedente0,1522
Aperto0,0000
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume9.324
Media Volume8.662
Capitalizzazione27.303
Beta (5 anni mensile)0,16
Rapporto PE (ttm)N/D
EPS (ttm)-0,6030
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

    Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros allotted to the development of new innovative treatments, after discontinuation of the REFRESH study PARIS, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications that directly target the brain to treat resistant h

  • GlobeNewswire

    Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share

    PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain to treat resistant/difficult to treat hypertension and heart-failure, today announces the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies. With the initiation report entitled “The shape of my heart”, p

  • GlobeNewswire

    Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity

    PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain to treat resistant/difficult to treat hypertension and heart-failure, today published its first half 2022 results. Jean-Philippe Milon, CEO of Quantum Genomics, commented: "Quantum Genomics continues its development trajectory aiming to put a new class of innovative medic